stockrowEnvista Holdings Corporation
NVST Healthcare Medical Instruments & Supplies
Envista Holdings Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, up 8.32% from fiscal 2024.
- Revenue
- +3.22%
- EPS
- +1,855.6%
- Free cash flow
- −6.48%
- Total debt
- −1.13%
Quarter to September 2026, against a year earlier
Follow NVST
Alert me
Envista Holdings Corporation (NVST) EBITDA
Envista Holdings Corporation's EBITDA for fiscal 2025 was $371.0M, compared with −$878.8M in fiscal 2024. Over the twelve months to 30 June 2026 it was $428.9M. Over the past ten years it has ranged from −$878.8M (fiscal 2024) to $564.0M (fiscal 2016); the current reading is higher than 40% of that period. Envista Holdings Corporation ranks 14th of 47 Medical Instruments & Supplies companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $371.0M | — |
| FY2024 | −$878.8M | — |
| FY2023 | $198.7M | (59.06%) |
| FY2022 | $485.4M | 0.83% |
| FY2021 | $481.4M | 118.82% |
| FY2020 | $220.0M | (45.52%) |
| FY2019 | $403.8M | (5.74%) |
| FY2018 | $428.4M | (15.67%) |
| FY2017 | $508.0M | (9.93%) |
| FY2016 | $564.0M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | $118.5M | 16.40% |
| Mar 2026 | $101.8M | (9.35%) |
| Dec 2025 | $112.3M | 16.61% |
| Sep 2025 | $96.3M | 11.98% |
| 27 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| NVST Envista Holdings Corporation | $428.9M |
| MMSI Merit Medical Systems, Inc. compare | $359.6M |
| STVN Stevanato Group S.p.A. compare | $351.1M |
| ICUI ICU Medical, Inc. compare | $314.2M |
| TFX Teleflex Incorporated compare | $256.2M |
| WRBY Warby Parker Inc. compare | $59.0M |
| ATRC AtriCure, Inc. compare | $34.2M |
| MMED MiniMed Group, Inc. compare | −$8.0M |
| PLSE Pulse Biosciences, Inc compare | −$82.0M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on NVST
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement